Filgotinib Demonstrates Favorable Safety in Pooled Analysis of Phase III Studies in Patients With Rheumatoid Arthritis

November 8-13, 2019; Atlanta, Georgia
Results of this pooled analysis of 3 randomized, controlled phase III trials show filgotinib to be well tolerated, with no new safety signals, and low rates of MACE/VTE.
Format: Microsoft PowerPoint (.ppt)
File Size: 192 KB
Released: November 18, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Related Content

CCO faculty Dr. Jonathan Kay’s viewpoint on data from 2019 ACR/ARP on novel approaches for treatment of RA

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 9, 2020 Expiration: January 8, 2021

CCO faculty Dr. Stanley Cohen’s viewpoint on data from 2019 ACR/ARP on investigational and approved JAK inhibitors for RA

Stanley B. Cohen, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 5, 2019 Expiration: December 4, 2020

7-year baricitinib safety data in RA patients consistent with earlier reports and acceptable considering efficacy from 2019 ACR, as reported by CCO; safety evaluations ongoing

Released: November 25, 2019

Latest data on IRAK4 inhibitor PF-06650833 in moderately to severely active RA presented at ACR/ARHP 2019 as reported by Clinical Care Options (CCO)

Released: November 18, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?